CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma.

JHEP reports : innovation in hepatology(2023)

引用 2|浏览19
暂无评分
摘要
An increase in portal pressure strongly impacts outcomes after surgery in patients with early hepatocellular carcinoma (HCC). Direct measurement through hepatic vein catheterization remains the reference standard for portal pressure assessment, but its invasiveness limits its application. Therefore, we evaluated the ability of CT scan-based liver and spleen volume measurements to predict portal hypertension in patients with HCC. Our results indicate that the newly described index, based on quantification of liver and spleen volume, accurately predicts portal hypertension. These results suggest that a single imaging test may be used to diagnose and stage HCC, while providing an accurate estimation of portal hypertension, thus helping to stratify surgical risks.
更多
查看译文
关键词
CSPH, clinically significant portal hypertension,DAAs, direct-acting antivirals agents,HCC, hepatocellular carcinoma,HVPG, hepatic venous pressure gradient,LSPS, liver stiffness-spleen size-to-platelet ratio score,LSVR, liver segmental volume,LV, liver volume,LV/SV, liver/spleen volume ratio,MAFLD, metabolic dysfunction-associated fatty liver disease,MDCT, multidetector computerised tomography,NITs, non-invasive tests,PSR, platelet count to spleen diameter ratio,SV, spleen volume,TE, transient elastography,VI, volume index,cirrhosis,cross-sectional imaging,hepatocellular carcinoma,non-invasive test,organ size,portal hypertension,predictive model
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要